Bi-, Tri-Specific Antibody and ADC Reference Antibody
|
Bi-Specific Tri-Specific Reference Antibody List |
||||||
|
Cat. No. |
Antibody Name |
Commercial Name |
Format |
Target |
Originator |
Disease/Indications |
|
BA001 |
Tibulizumab |
N/A |
IgG-scFv |
IL-17 & BAFF |
Eli Lilly |
Autoimmune inflammation (investigational) |
|
BA002 |
Cadonilimab |
N/A |
IgG-scFv |
PD-1 & CTLA4 |
Akeso |
Cervical cancer (China); other solid tumors (trials) |
|
BA003 |
Pm8002 |
N/A |
IgG-VHH |
PD-L1 & VEGF |
BioNTech |
Solid tumors (trials) |
|
BA004 |
Lutikizumab |
N/A |
DVD-Ig |
IL-1α & IL-1β |
AbbVie |
Osteoarthritis pain; hidradenitis suppurativa (trials) |
|
BA005 |
Erfonrilimab |
N/A |
VHH-VHH-Fc |
PD-L1 & CTLA4 |
Alphamab Oncology |
PD-L1×CTLA-4 solid tumors (trials) |
|
BA006 |
Sonelokimab |
N/A |
VHH-VHH-VHH |
IL-17 & IL-17F & HSA |
Sanofi |
Psoriasis; hidradenitis suppurativa (trials) |
|
BA007 |
Duligotuzumab |
N/A |
IgG-like |
EGFR & HER3 |
Roche |
Head & neck SCC; mCRC (trials, no benefit) |
|
BA008 |
Epcoritamab |
Epkinly / Tepkinly |
IgG-like |
CD3 & CD20 |
Genmab BioPharma |
DLBCL; FL (approved) |
|
BA009 |
Rilvegostomig |
N/A |
IgG-like |
PD-1 & TIGIT |
AstraZeneca |
PD-1×TIGIT solid tumors (trials) |
|
BA010 |
Elranatamab |
N/A |
IgG-like |
CD3 & BCMA |
Pfizer |
Relapsed/refractory multiple myeloma (approved) |
|
BA011 |
Sotiburafusp alfa |
N/A |
IgG-Fusion Protein |
PD-L1 & VEGF |
Huabo Biopharm |
Solid tumors (trials) |
|
BA012 |
Tqb2858 |
N/A |
IgG-VHH |
PD-L1 & TGF-β |
Chia Tai Tian Qing Pharmaceutical |
PD-L1×TGFβ solid tumors (trials) |
|
BA013 |
Istiratumab |
N/A |
IgG-scFv |
HER3 & IGF-1R |
Merrimack Pharma |
Pancreatic cancer (trials) |
|
BA014 |
Hx009 |
N/A |
IgG-Fusion Protein |
PD-1 & CD47 |
Hangzhou Hanx Biopharmaceutical |
CD47×PD-1 solid tumors (trials) |
|
BA015 |
Glofitamab |
Columvi |
IgG-Fab |
CD3 & CD20 |
Roche |
DLBCL/LBCL (approved) |
|
BA016 |
TNB-383B |
N/A |
Half IgG+ScFv |
CD3 & BCMA |
TeneoBio |
Multiple myeloma (trials) |
|
BA017 |
Mas825 |
N/A |
IgG-like |
IL-18 & IL-1β |
Novartis |
Inflammatory diseases (trials) |
|
BA018 |
Romilkimab |
N/A |
DVD-Ig |
IL-13 & IL-4 |
Sanofi |
Systemic sclerosis; atopic dermatitis (trials) |
|
BA019 |
Linvoseltamab |
Lynozyfic |
IgG-like |
CD3 & BCMA |
Regeneron Pharmaceuticals |
Multiple myeloma (trials) |
|
BA020 |
Abt-122 |
N/A |
DVD-Ig |
IL-17 & TNF-α |
AbbVie |
See Lutikizumab (IL-1α/β) |
|
BA021 |
Mosunetuzumab |
N/A |
IgG-like |
CD3 & CD20 |
Roche |
Follicular lymphoma (approved); other B-cell NHL (trials) |
|
BA022 |
Gefurulimab |
N/A |
VHH-VHH |
C5 & HSA |
AstraZeneca |
Complement-mediated diseases (trials) |
|
BA023 |
Enristomig |
N/A |
VHH-VHH-Fc |
PD-L1 & 4-1BB |
Inhibrx |
4-1BB×PD-L1 solid tumors (trials) |
|
BA024 |
Anbenitamab |
N/A |
IgG-like |
HER2 |
Alphamab Oncology |
HER2+ solid tumors (trials) |
|
BA026 |
Talquetamab |
Talvey |
IgG-like |
CD3 & GPRC5D |
Genmab BioPharma, Johnson & Johnson |
Relapsed/refractory multiple myeloma (approved) |
|
BA027 |
Izalontamab |
N/A |
IgG-scFv |
EGFR & HER3 |
SystImmune Inc, Sichuan Baili Pharmaceutical |
EGFR×HER3 solid tumors (trials) |
|
BA028 |
Mgd010 |
N/A |
DART-Fc |
CD32b & CD79b |
MacroGenics |
B-cell malignancies/autoimmune (trials) |
|
BA029 |
Teclistamab |
N/A |
IgG-like |
CD3 & BCMA |
Johnson & Johnson |
Relapsed/refractory multiple myeloma (approved) |
|
BA030 |
Alnuctamab |
N/A |
IgG-Fab |
CD3 & BCMA |
Bristol Myers Squibb |
BCMA×CD3 multiple myeloma (trials) |
|
BA031 |
Davutamig |
N/A |
IgG-like |
cMet |
Regeneron Pharmaceuticals |
c-MET+ solid tumors (trials) |
|
BA032 |
Emb-01 |
N/A |
Fab-IgG |
EGFR & cMet |
Epimab Biotherapeutics |
EGFR×c-MET tumors (trials) |
|
BA033 |
RO7122290 |
N/A |
IgG-VHH |
4-1BB & FAP |
Roche |
FAP×4-1BB solid tumors (trials) |
|
BA034 |
Gen1042 |
N/A |
IgG-like |
4-1BB & CD40 |
BioNTech, Genmab BioPharma |
4-1BB×CD40 solid tumors (trials) |
|
BA035 |
Hpn536 |
N/A |
BiTE |
CD3e & MSLN & HSA |
Harpoon Therapeutics |
Mesothelin+ ovarian/pancreatic cancer (trials) |
|
BA036 |
Gen3009 |
N/A |
IgG-like |
CD37 |
Genmab BioPharma |
CD37 B-cell malignancies (trials) |
|
BA037 |
Gen1044 |
N/A |
IgG-like |
CD3 & TPBG |
Genmab BioPharma |
5T4+ solid tumors (trials) |
|
BA038 |
Regn7075 |
N/A |
IgG-like |
EGFR & CD28 |
Regeneron Pharmaceuticals |
EGFR+ solid tumors (trials) |
|
BA039 |
Yh32367 |
N/A |
IgG-scFv |
4-1BB & HER2 |
ABLBio, Yuhan Corporation |
HER2+ solid tumors (trials) |
|
BA040 |
Emb-06 |
N/A |
Fab-IgG |
CD3 & BCMA |
Epimab Biotherapeutics |
BCMA×CD3 multiple myeloma (trials) |
|
BA041 |
Ngm707 |
N/A |
IgG-like |
LILRB1 & LILRB2 |
NGM Biopharmaceuticals |
LILRB1/2 solid tumors (trials) |
|
BA042 |
Ibi-334 |
N/A |
IgG-like |
B7H3 & EGFR |
Innovent |
B7-H3×EGFR solid tumors (trials) |
|
BA043 |
Cova322 |
N/A |
IgG-VHH |
IL-17 & TNF-α |
Covagen |
Psoriasis; HS (discontinued) |
|
BA044 |
Tobemstomig |
N/A |
IgG-like |
PD-1 & LAG-3 |
Roche |
LAG-3×PD-1 solid tumors (trials) |
|
BA045 |
Odronextamab |
N/A |
IgG-like |
CD3 & CD20 |
Regeneron Pharmaceuticals |
FL, DLBCL (EU approved) |
|
BA046 |
Ozoralizumab |
N/A |
VHH-VHH-VHH |
TNF-α & HSA |
Ablynx |
Rheumatoid arthritis (Japan) |
|
BA047 |
Gen1047 |
N/A |
IgG-like |
CD3 & B7-H4 |
Genmab BioPharma |
B7-H4+ solid tumors (trials) |
|
BA048 |
Amivantamab |
Rybrevant |
IgG-like |
EGFR & cMet |
Genmab BioPharma, Johnson & Johnson |
NSCLC (EGFR exon20ins, approved); GBM (trial) |
|
BA049 |
Afm24 |
N/A |
IgG-scFv |
EGFR & CD16a |
Affimed |
EGFR+ solid tumors (trials) |
|
BA051 |
Hpn328 |
N/A |
BiTE |
CD3 & DLL3 & HSA |
Harpoon Therapeutics |
SCLC; DLL3+ tumors (trials) |
|
BA052 |
Amulirafusp alfa |
N/A |
IgG-Fusion Protein |
CD20 & CD47 |
ImmuneOnco Biopharmaceuticals |
B-cell NHL (trials) |
|
BA053 |
Volrustomig |
N/A |
IgG-like |
PD-1 & CTLA4 |
AstraZeneca |
PD-1×CTLA-4 RCC, NSCLC (trials) |
|
BA054 |
Faricimab |
Vabysmo |
IgG-like |
VEGF & ANG2 |
Roche |
nAMD; DME; RVO (approved) |
|
BA055 |
Reozalimab |
N/A |
IgG-like |
PD-L1 & PD-1 |
Innovent |
PD-1×PD-L1 solid tumors (trials) |
|
BA056 |
Ivonescimab |
N/A |
IgG-scFv |
VEGF & PD-1 |
Akeso-Sino Pharma |
NSCLC (China approved); broader NSCLC (trials) |
|
BA057 |
Acasunlimab |
N/A |
IgG-like |
PD-L1 & 4-1BB |
BioNTech, Genmab BioPharma |
4-1BB×PD-L1 NSCLC, solid tumors (trials) |
|
BA058 |
Navicixizumab |
N/A |
IgG-like |
VEGF & DLL4 |
OncoMed Pharmaceuticals |
Platinum-resistant ovarian cancer (trials) |
|
BA059 |
Apv-527 |
N/A |
ScFv-Fc-ScFv |
4-1BB & TPBG |
Alligator Bioscience, Aptevo Therapeutics |
5T4+ solid tumors (trials) |
|
BA060 |
Zanidatamab |
Ziihera |
Half IgG+ScFv |
HER2 |
Zymeworks |
HER2+ BTC (approved); gastric/other HER2+ tumors (trials) |
|
BA061 |
Tebotelimab |
N/A |
DART-DART-Fc |
PD-1 & LAG-3 |
MacroGenics |
LAG-3×PD-1 solid tumors (trials) |
|
BA062 |
Emb-02 |
N/A |
Fab-IgG |
PD-1 & LAG-3 |
Epimab Biotherapeutics |
LAG-3×PD-1 solid tumors (trials) |
|
BA063 |
Emicizumab |
Hemlibra |
IgG-like |
Factor IX & Factor X |
Roche |
Hemophilia A prophylaxis (approved) |
|
BA064 |
Nivatrotamab |
N/A |
IgG-scFv |
CD3 & GD2 |
Memorial Sloan Kettering Cancer Center |
Neuroblastoma; GD2+ tumors (trials) |
|
BA066 |
Ubamatamab |
N/A |
IgG-like |
CD3 & CA125 |
Regeneron Pharmaceuticals |
Ovarian cancer (trials) |
|
BA067 |
Vanucizumab |
N/A |
IgG-like |
VEGF & ANG2 |
Roche |
Ang2×VEGF solid tumors (discontinued) |
|
BA068 |
Blinatumomab |
Blincyto |
BiTE |
CD3 & CD19 |
Amgen |
B-ALL (approved) |
|
BA069 |
Vudalimab |
N/A |
Half IgG+ScFv |
PD-1 & CTLA4 |
Xencor |
mCRPC; solid tumors (trials) |
|
BA070 |
Zenocutuzumab |
Bizengri |
IgG-like |
HER3 & HER2 |
Merus |
NRG1 fusion+ NSCLC; pancreatic cancer (approved) |
|
BA071 |
Lomvastomig |
N/A |
IgG-like |
PD-1 & TIM-3 |
Roche |
PD-1×TIM-3 solid tumors (trials) |
|
BA072 |
Tarlatamab |
N/A |
HLE-BiTE |
CD3 & DLL3 |
Amgen |
Extensive-stage SCLC (approved) |
|
BA073 |
M701 |
N/A |
Half IgG+ScFv |
CD3 & EpCAM |
Wuhan Youzhiyou Biopharmaceutical |
EpCAM+ solid tumors (trials) |
|
BA074 |
Nezastomig |
N/A |
IgG-like |
CD28 & PSMA |
Regeneron Pharmaceuticals |
PSMA+ prostate cancer (trials) |
|
BA075 |
Flotetuzumab |
N/A |
DART-DART |
CD3 & CD123 |
MacroGenics |
Relapsed AML (trials) |
|
These antibody products are for research use only. |
||||||
